What Is ImmunityBio, Inc. (IBRX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, ImmunityBio, Inc.'s intrinsic value is estimated at $3.55, suggesting the stock is overvalued at its current price of $7.73. With 9 out of 11 models flagging downside (-54.1% average return), the market may be pricing in unsustainable growth. The most optimistic model, Markov DDM, places fair value at $16.30 (+110.8%), while EPV — the most conservative — estimates $0.17 (-97.9%). This +208.7% gap reflects genuine analytical uncertainty about ImmunityBio, Inc.'s intrinsic worth. Among models with highest confidence, Markov DDM lean bullish — adding weight to the bullish side of the thesis.
What Do the Models Say About IBRX?
11 of 13 models are currently active for IBRX. Of these, 1 model suggests upside while 10 models suggest overvaluation. The Bayesian DCF estimates IBRX's intrinsic value at $1.80, implying -76.7% downside from the current price. See which stocks rank higher →
How Does IBRX Rank in Biological Products, (No Diagnostic Substances)?
Among 134 Biological Products, (No Diagnostic Substances) stocks, IBRX ranks #50 by Quality of Company score. CirclFi's QOC score of 5.9/10 evaluates 32 fundamental signals. A score of 5.9 reflects mixed fundamentals.
See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →
ImmunityBio, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is IBRX a Value Trap?
CirclFi's Value Trap algorithm assigns IBRX a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
11 of 13 models are active for ImmunityBio, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, ImmunityBio, Inc.'s fundamental quality profile registers 5.9/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +208.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every IBRX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across IBRX's 11 active models, average confidence is 22%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad